Tiratricol-induced periodic paralysis: A review of nutraceuticals affecting thyroid function

Endocrine Practice

Volumn 17, Issue 4, 2011, Pages 610-615

  Cohen Lehman, Janna ^a   Charitou, Marina M ^b   Klein, Irwin ^c  

^a Northwell Health   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IODINE 123; LIOTHYRONINE; NUTRACEUTICAL; POTASSIUM; THYROID HORMONE; THYROTROPIN; THYROXINE; TIRATRICOL;

ADULT; BODY BUILDING; CASE REPORT; DIAPHORESIS; DIET SUPPLEMENTATION; HOSPITALIZATION; HUMAN; HYPERTHYROIDISM; HYPOKALEMIA; LEG; MALE; PERIODIC PARALYSIS; POTASSIUM BLOOD LEVEL; REVIEW; THYROID FUNCTION; THYROTOXIC PERIODIC PARALYSIS; WEIGHT REDUCTION;

EID: 84860406591     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP10137.RA     Document Type: Review

References (45)

1. Klein I, Levey GS. Thyroid myopathy. Thyroid Today. 1983;6:1-6.
2. Lin SH. Thyrotoxic periodic paralysis. Mayo Clin Proc. 2005;80:99-105.
3. Klein I, Ojamaa K. Thyroid (neuro)myopathy. Lancet. 2000;356:614. (Pubitemid 30627586)
4. Mechanick JI, Brett EM, Chausmer AB, Dickey RA, Wallach S (American Association of Clinical Endocrinologists). American Association of Clinical Endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceuticals [published correction appears in Endocr Pract. 2008;14:802-803].
5. Endocr Pract. 2003;9:417-470.
6. Timbo BB, Ross MP, McCarthy PV, Lin CT. Dietary supplements in a national survey: prevalence of use and reports of adverse events. J Am Diet Assoc. 2006;106:1966-1974. (Pubitemid 44779443)
7. Dietary Supplement Health and Education Act of 1994. Pub L No. 103-417, 21 USC §3419.
8. Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann Intern Med. 2001;135(8, pt 1):594-600. (Pubitemid 33010195)
9. Food and Drug Administration. FDA warns against consuming dietary supplements containing tiratricol. Rockville MD: National Press Offce; November, 11 1999. Talk Paper T99-52.
10. Food and Drug Administration. FDA warns against consuming dietary supplements containing tiratricol. Rockville MD: National Press Offce; November 21 2000. Talk Paper T00-64.
11. FDA U.S. Food and Drug Administration. Center for Food Safety and Applied Nutrition continued 2001. United States v. Syntrax Innovations, Inc., 149 F. Supp. 2d 880, 882-891 (E.D. Mo. 2001). http://www.fda.gov/ICECI/ EnforcementActions/EnforcementStory/EnforcementStoryArchive/ucm107292.htm. Accessed for verifcation April 11, 2011.
12. Scally MC, Hodge A. A report of hypothyroidism induced by an over-the-counter fat loss supplement (tiratricol). Int J Sport Nutr Exerc Metab. 2003;13:112-116. (Pubitemid 36383158)
13. Bauer BA, Elkin PL, Erickson D, Klee GG, Brennan MD. Symptomatic hyperthyroidism in a patient taking the dietary supplement tiratricol. Mayo Clin Proc. 2002; 77:587-590. (Pubitemid 34587349)
14. Takeda T, Suzuki S, Liu RT, DeGroot LJ. Triiodothyroacetic acid has unique potential for therapy of resistance to thyroid hormone. J Clin Endocrinol Metab. 1995;80:2033-2040.
15. Sherman SI, Ringel MD, Smith MJ, Kopelen HA, Zoghbi WA, Ladenson PW. Augmented hepatic and skeletal thy-romimetic effects of tiratricol in comparison with levothy-roxine. J Clin Endocrinol Metab. 1997;82:2153-2158. (Pubitemid 27287576)
16. Kung AW. Clinical review: thyrotoxic periodic paralysis; a diagnostic challenge. J Clin Endocrinol Metab. 2006;91: 2490-2495. (Pubitemid 44024605)
17. Hannon MJ, Behan LA, Agha A. Thyrotoxic periodic paralysis due to excessive L-thyroxine replacement in a Caucasian man. Ann Clin Biochem. 2009;46(pt 5):423-425.
18. Chen YC, Fang JT, Chang CT, Chou HH. Thyrotoxic periodic paralysis in a patient abusing thyroxine for weight reduction. Ren Fail. 2001;23:139-142.
19. Akinyemi E, Bercovici S, Niranjan S, Paul N, Hemavathy B. Thyrotoxic hypokalemic periodic paralysis due to dietary weight-loss supplement [published online ahead of print January 8, 2010]. Am J Ther. PMID: 20068442.
20. Chou HK, Tsao YT, Lin SH. An unusual cause of thy-rotoxic periodic paralysis: triiodothyronine-containing weight reducing agents. Am J Med Sci. 2009;337:71-73.
21. Pothiwala P, Levine SN. Analytic review: thyrotoxic periodic paralysis; a review. J Intensive Care Med. 2010;25: 71-77.
22. Chan A, Shinde R, Chow CC, Cockram CS, Swaminathan R. In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis. BMJ. 1991;303:1096-1099.
23. Ko GT, Chow CC, Yeung VT, Chan HH, Li JK, Cockram CS. Thyrotoxic periodic paralysis in a Chinese population. QJM. 1996;89:463-468. (Pubitemid 26184332)
24. Ryan DP, da Silva MR, Soong TW, et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell. 2011;140:88-98.
25. Dassau L, Conti LR, Radeke CM, Ptácek LJ, Vandenberg CA. Kir2.6 regulates the surface expression of Kir2.x inward rectifer potassium channels. J Biol Chem. 2011;18:9526-9541.
26. Chan A, Shinde R, Chow CC, Cockram CS, Swaminathan R. Hyperinsulinaemia and Na+, K(+)-ATPase activity in thyrotoxic periodic paralysis. Clin Endocrinol (Oxf). 1994;41:213-216. (Pubitemid 24239926)
27. McManis PG, Lambert EH, Daube JR. The exercise test in periodic paralysis. Muscle Nerve. 1986;9:704-710. (Pubitemid 16020212)
28. Ng WY, Lui KF, Thai AC, Cheah JS. Absence of ion channels CACN1AS and SCN4A mutations in thyrotoxic hypokalemic periodic paralysis. Thyroid. 2004;14:187-190. (Pubitemid 38452190)
29. Tang NL, Chow CC, Ko GT, et al. No mutation in the KCNE3 potassium channel gene in Chinese thyrotoxic hypokalaemic periodic paralysis patients. Clin Endocrinol (Oxf). 2004;61:109-112. (Pubitemid 38951653)
30. Medeiros-Neto G, Kallas WG, Knobel M, Cavaliere H, Mattar E. Triac (3,5,3′-triiodothyroacetic acid) partially inhibits the thyrotropin response to synthetic thyro-tropin-releasing hormone in normal and thyroidectomized hypothyroid patients. J Clin Endocrinol Metab. 1980;50: 223-225. (Pubitemid 10161451)
31. Bracco D, Morin O, Schutz Y, Liang H, Jéquier E, Burger AG. Comparison of the metabolic and endocrine effects of 3,5,3′- triiodothyroacetic acid and thyroxine. J Clin Endocrinol Metab. 1993;77:221-228. (Pubitemid 23206807)
32. Menegay C, Juge C, Burger AG. Pharmacokinetics of 3,5,3′- triiodothyroacetic acid and its effects on serum TSH levels. Acta Endocrinol (Copenh). 1989;121:651-658. (Pubitemid 19281004)
33. Danzi S, Ojamaa K, Klein I. Triiodothyronine-mediated myosin heavy chain gene transcription in the heart. Am J Physiol Heart Circ Physiol. 2003;284:H2255-H2262. (Pubitemid 36622439)
34. Bentin J, Désir D, Mockel J. Triac (3,5,3′-triiodo-thyro- acetic acid) induced "pseudohypothyroidism." Acta Clin Belg. 1984;39:285-289.
35. Chan WB, Chow CC, Cockram CS. A patient with low free T4 and low thyroid-stimulating hormone without hypopituitarism. Int J Clin Pract. 2004;58:983-984. (Pubitemid 39642623)
36. Braverman LE. Iodine and the thyroid: 33 years of study. Thyroid. 1994;4:351-356. (Pubitemid 24295435)
37. Daniels GH. Amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 2001;86:3-8.
38. Vagenakis AG, Wang CA, Burger A, Maloof F, Braverman LE, Ingbar SH. Iodide-induced thyrotoxico-sis in Boston. N Engl J Med. 1972;287:523-527.
39. Müssig K, Thamer C, Bares R, Lipp HP, Häring HU, Gallwitz B. Iodine-induced thyrotoxicosis after ingestion of kelp-containing tea. J Gen Intern Med. 2006;21:C11-C14. (Pubitemid 43801480)
40. Clark CD, Bassett B, Burge MR. Effects of kelp supplementation on thyroid function in euthyroid subjects. Endocr Pract. 2003;9:363-369.
41. Eliason BC, Doenier JA, Nuhlicek DN. Desiccated thyroid in a nutritional supplement. J Fam Pract. 1994;38:287-288. (Pubitemid 24093917)
42. Sawin CT, London MH. "Natural" desiccated thyroid: a "health-food" thyroid preparation. Arch Intern Med. 1989;149:2117-2118. (Pubitemid 19232237)
43. Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010;362:906-916.
44. Brenta G, Danzi S, Klein I. Potential therapeutic applications of thyroid hormone analogs. Nat Clin Pract Endocrinol Metab. 2007;3:632-640. (Pubitemid 47294432)
45. Ladenson PW, McCarren M, Morkin E, et al. Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study. J Clin Endocrinol Metab. 2010;95:1349-1354.